Pirlimycin hydrochloride, CAS 79548-73-5, is supplied as a veterinary-grade lincosamide active pharmaceutical ingredient for manufacture of intramammary infusions and, with appropriate downstream validation, other dosage forms including tablets, injections, capsules, powders, granules, premix, and solutions. The product is released in two model-designated grades: PIR-IM-100 for sterile micronized material meeting endotoxin and particle-size requirements for intramammary suspensions, and PIR-API-200 for non-sterile crystalline material intended for oral or feed-based dosage forms. The molecule binds to the 23S rRNA of the 50S ribosomal subunit and inhibits peptide bond formation. The approved veterinary indication is treatment of clinical mastitis in lactating dairy cattle associated with susceptible staphylococci and streptococci. The registered intramammary infusion product has a milk withholding time of 36 h and a slaughter withdrawal interval of 28 d; these residue-depletion values apply only to the approved finished product and require separate validation for any compounded or reformulated product.

Pirlimycin is not active against Gram-negative coliform mastitis pathogens or Mycoplasma spp.; empirical monotherapy in herds with coliform involvement is therefore contraindicated unless culture and susceptibility data support lincosamide therapy. The API has no beta-lactam ring and therefore no cross-reactivity with beta-lactam hypersensitivity responses in the target animal.

Why does pirlimycin occupy a narrower mastitis-therapy niche than lincomycin or clindamycin?

The regulatory and clinical positioning of pirlimycin differs from lincomycin and clindamycin even though all three are lincosamides. Lincomycin hydrochloride is used predominantly in injectable, water-soluble, and feed-premix formulations for swine and poultry; its intramammary use in lactating dairy cattle is not a principal registered indication. Clindamycin hydrochloride is used mainly in companion animals and is not approved for food-producing species in the major dairy-producing jurisdictions. Pirlimycin hydrochloride is the lincosamide developed specifically for intramammary infusion in lactating cattle, with an approved residue-depletion profile established for milk and tissues.

Compared with beta-lactam intramammary preparations such as cephapirin or amoxicillin, pirlimycin does not contain a beta-lactam ring. The difference is relevant in veterinary practice when a non-beta-lactam therapeutic alternative is desired, but the antimicrobial spectrum remains narrow. Pirlimycin has limited activity against Gram-negative organisms and no activity against mycoplasma mastitis agents. The decision to use pirlimycin instead of a beta-lactam, aminoglycoside, or macrolide intramammary product should be supported by milk culture and susceptibility testing according to CLSI VET01 or equivalent methodology.

Release testing for sterile micronized pirlimycin hydrochloride is more stringent than release testing for non-sterile oral or premix grades because the intramammary route bypasses the gastrointestinal barrier and introduces the product into an inflamed mammary gland. Table 2 lists representative release criteria for PIR-IM-100. The values are target release limits derived from current good manufacturing practice for sterile veterinary APIs; batch-specific limits must be validated against the approved finished-product specification and confirmed on three consecutive production batches.

Sterile suspension manufacturing and the particle-size boundary for syringeability

For PIR-IM-100, the critical physical attribute is not chemical purity alone but particle-size distribution. Intramammary suspensions must pass through a narrow teat cannula without clogging, while remaining sufficiently uniform to deliver the intended dose. A laser diffraction D90 of ≤15 µm is a typical upper boundary for syringeability and content uniformity in oil or aqueous intramammary suspensions. Production-scale rotor-stator dispersion has shown that batch-to-batch variance in particle size increases when the API is exposed to high-shear mixing for extended periods without temperature control; the suspension may undergo local viscosity reduction and subsequent sedimentation. Therefore, dispersion is typically performed in jacketed vessels maintained at 15–25 °C, with recirculation through a high-shear mixer at controlled tip speed. Terminal sterilization of aqueous suspensions may be limited by thermal sensitivity of the lincosamide ring; aseptic processing with sterile API is commonly used. Published data for specific stability of pirlimycin hydrochloride in terminal sterilization cycles is limited.

For PIR-API-200, the powder is intended for direct blending, wet granulation, or dry granulation. The crystalline material can exhibit cohesive flow at low moisture content, and pre-drying is required when storage relative humidity exceeds 60%. Granulation operations should maintain water activity below that which causes agglomeration and content uniformity failure. Bulk and tapped density are monitored according to Ph. Eur. 2.9.34, and flowability is characterized by Ph. Eur. 2.9.36. The API can be processed into tablets, capsules, powders, granules, and premixes only where the target species, indication, and residue-depletion profile have been established. Published data for oral bioavailability and tissue residues of pirlimycin in non-bovine species are limited.

If tablets, granules, or premix are requested, what changes in handling and specification become mandatory?

When the API is converted from an intramammary sterile grade to a non-sterile oral or feed-grade presentation, the microbiological quality criteria change, but the chemical purity requirements remain comparable. Non-sterile PIR-API-200 is released against a total aerobic microbial count of ≤10³ CFU/g and total combined molds and yeasts of ≤10² CFU/g, with absence of Salmonella and Escherichia coli in 25 g according to compendial microbiological examination methods. Residual solvents comply with VICH GL18, and degradation products are controlled by the same HPLC method used for the sterile grade.

Tablet compression of pirlimycin hydrochloride requires careful control of compaction force; the crystalline powder can undergo capping at high punch speeds if the binder level is insufficient. Production-scale observations indicate that direct compression formulations often require microcrystalline cellulose with a binder concentration in the range of 2%–5% dry weight to maintain tablet hardness without excessive friability. For wet granulation, the binder is added as an aqueous or hydroalcoholic solution, and the granulation end point is controlled by impeller power consumption and torque. Premix blends for medicated feed require stepwise dilution to achieve a coefficient of variation below 5% and to prevent carryover contamination in batch-to-batch changeovers.

For injectable solutions, the hydrochloride salt provides water solubility, but pH control and solution stability require formulation-specific validation. The sterile grade is not intended for terminal sterilization after reconstitution unless the finished-product stability profile demonstrates no degradation of the lincosamide ring. Each dosage form derived from PIR-IM-100 or PIR-API-200 requires a separate residue-depletion study in the target species; withholding periods cannot be transferred from the approved intramammary infusion to tablets, injections, capsules, powders, granules, premix, or solutions without species-specific data. Published data for this configuration is limited in non-bovine veterinary species.